Awaiting development: Guidance and quality standards

Showing 101 to 110 of 344

Guidance and quality standards awaiting development
Title	Type
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]	Technology appraisal guidance
Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [GID-TA12000]	Technology appraisal guidance
Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]	Technology appraisal guidance
Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]	Technology appraisal guidance